Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Figure 13

The targeted nicotinamide derivative’s FMO and TDOS at the B3LYP/6-311++G(d,p) level.